Bessemer Group Inc. Purchases 10,684 Shares of Abbott Laboratories $ABT

Bessemer Group Inc. grew its position in shares of Abbott Laboratories (NYSE:ABT) by 0.9% in the third quarter, according to its most recent filing with the SEC. The fund owned 1,211,430 shares of the healthcare product maker’s stock after acquiring an additional 10,684 shares during the quarter. Bessemer Group Inc. owned about 0.07% of Abbott Laboratories worth $162,260,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. IMG Wealth Management Inc. lifted its holdings in shares of Abbott Laboratories by 759.1% in the 2nd quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock valued at $26,000 after acquiring an additional 167 shares during the last quarter. Cloud Capital Management LLC purchased a new stake in Abbott Laboratories during the third quarter valued at approximately $29,000. Guerra Advisors Inc purchased a new position in shares of Abbott Laboratories in the 3rd quarter worth approximately $31,000. Anfield Capital Management LLC increased its position in shares of Abbott Laboratories by 81.3% during the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after purchasing an additional 104 shares during the last quarter. Finally, Delos Wealth Advisors LLC purchased a new stake in Abbott Laboratories during the 2nd quarter valued at $32,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $108.18 on Thursday. The firm has a market cap of $188.11 billion, a price-to-earnings ratio of 29.08, a PEG ratio of 1.73 and a beta of 0.75. Abbott Laboratories has a 52-week low of $105.27 and a 52-week high of $141.23. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. The company’s 50 day moving average is $121.62 and its 200 day moving average is $127.11.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The company had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. During the same quarter in the prior year, the business earned $1.34 earnings per share. Abbott Laboratories’s revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, sell-side analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Thursday, January 15th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.3%. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date is Thursday, January 15th. Abbott Laboratories’s payout ratio is presently 67.74%.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Oppenheimer cut their price objective on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Evercore ISI reduced their price objective on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Daiwa Capital Markets dropped their target price on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a research report on Friday, January 30th. Raymond James Financial reduced their price target on Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Finally, Freedom Capital upgraded Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 29th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $137.05.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.